What Andy Grove still gets wrong about the life sciences — and how he could help fix them
(UPDATED: See below.)
Like DNA co-discoverer James Watson, whose career ended last month after he linked genetic intelligence differences to race, former Intel chairman Andrew Grove seems to be falling into the trap of assuming that expertise in one field automatically translates into wisdom in others. In… Continue Reading
Biodel, drug reformulator, raises $75M in IPO
Danbury, Conn.-based Biodel priced a five million share initial offering at $15 per share, raising $75 million before fees and concessions. The offering priced in the middle of Biodel’s expected range of $14 to $16 per share, making it one of the more successful drug-related… Continue Reading
Biotech financing: Not everyone gets a turn at the firehose
Every trend has its counterexamples, and the rush of venture funding into biotechnology is no exception.
VentureWire reports today (subscription required) on the case of Sequella, a small Rockville, Md., biotech working on new therapies for drug-resistant tuberculosis (whose bacterium is pictured at left). The… Continue Reading